临床药师参与一例糖皮质激素性骨质疏松症患者治疗的病例分析被引量：2

下载PDF

导出

摘要目的探讨临床药师参与患者药物治疗过程中的作用。方法通过临床药师参与1例糖皮质激素性骨质疏松症(GIOP)的治疗,介绍临床药师应用不良反应因果关系协助临床医师判断GIOP,以及对患者进行药学监护的过程和体会。结果临床药师以专业特长参与临床治疗,可提高药物治疗水平。结论临床药师应积极参与临床治疗,在临床实践中提高专业水平,发挥作用和体现价值。

作者王芳

机构地区四川省阿坝州食品药品检验所

出处《临床合理用药杂志》 2015年第30期132-133,共2页 Chinese Journal of Clinical Rational Drug Use

关键词骨质疏松糖皮质激素类药剂师

分类号 R580 [医药卫生—内分泌]

引文网络
相关文献

参考文献7

1Seibel M J, Cooper MS, Zhou H. Glucocorticoid - induced osteoporosis : mechanisms, management, and future perspectives [ J ]. Lancet Dia- betes Endocrinol, 2013, 1 (1) : 59 -70.
2Avner M, Finkelstein Y, Hackam D, et al. Establishing causality in pediatric adverse drug reactions: use of the Naranjo probability scale [J]. Paediatr Drugs, 2007, 9 (4): 267-270.
3Tanaka Y. Pathogenesis of glucocorticoid - induced osteopomsis [ J ]. Clin Calcium, 2014, 24 (9) : 1289 -1294.
4Compston J. Management of glucocorticoid - induced osteoporosis [ J ]. Nat Rev Rheumatol, 2010, 6 (2): 82-88.
5叶华,邹亮,陈适,栗占国.风湿科医生对糖皮质激素性骨质疏松症认识的调查[J].中国骨质疏松杂志,2009,15(1):56-59. 被引量：8
6Grossman JM, Gordon R, Ranqanath VK, et al. American Colllege of Rheumatology 2010 recommendations for the prevention andtrearment of Glucocorticoid - Induced osteoporosis [ J ]. Arthritis Care Res, 2010, 62 (11): 1515-1526.
7Miki T, Okamoto K. Efficacy of active vitamin D on glucocorticoid - in- duced osteoporosis [ J ]. Clin Calcium, 2014, 24 (9): 1387 - 1392.

二级参考文献11

1糖皮质激素性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):460-461. 被引量：27
2Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med, 1994,96(2) :115-123.
3Walsh LJ, Wang CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ,1996,313(7053) :344-346.
4American College of Rheumatology Ad Hoc Committee Glucoeorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum,2001,44(7) : 1496-1503.
5Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res,2000,15(6) : 993-1000.
6Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med, 1993, 119(10) : 963-968.
7Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid-induced osteoporosis : a meta-analytic approach. Arthritis Rheum, 1999,42 (8) : 1740-1751.
8Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum, 1999,42( 11 ) : 2309-2318.
9Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebocontrolled extension trial. Arthritis Rheum,2001,44( 1 ):202-211.
10Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum, 1994, 37(10): 1499-1505.